Compugen at Leerink Global Healthcare Conference: Strategic Insights

Compugen presented program updates: AstraZeneca is running 11 phase 3 trials with rilvegostomig (bispecific PD-1/TIGIT) with AZ guiding phase 3 readouts post-2027. Compugen’s MAIA ovarian trial tests COM701 monotherapy in platinum-sensitive patients (40 on drug / 20 placebo), excluding liver metastases, aiming to detect a meaningful PFS signal (targeting ~3 months improvement). Gilead-partnered GS-0321 (IL-18 BP) dosed its first patient in early 2025 and is in dose escalation with mono and combo arms. The company is also advancing its Unigen AI-driven discovery platform but provided no near-term timelines for new programs.

Analysis

Validation of a bispecific IO backbone would be an industry-level regime shift: it re-prices combination economics (one molecule replacing two biologics), concentrates commercial leverage at partners who can execute complex combo trials, and creates durable demand for specialized CMO capabilities (site-specific conjugation, bispecific platforms). That implies near-term winners are those with execution scale and downstream manufacturing optionality rather than small single-target developers.

For the smaller, mechanism-focused developer, the critical second-order variable is translational fidelity of ex vivo systems to durable clinical benefit — not just ORR. A replicable niche signal that produces durable PFS/DoR in earlier-line, low-burden populations will unlock accelerated pathways; short-lived tumor debulking signals will not. Biomarker engineering (digital pathology/QC-type classifiers) is therefore a gating factor: mis-specification inflates false positives in early cohorts and causes costly phase 3 misses.

Key near-term risks are binary translational failure, biomarker miscalibration, and combo tolerability that forces dose compromises. Time arbitrage sits in multi-quarter to multi-year windows: translational cohorts and randomized maintenance endpoints will move probability-of-success materially well before broad commercial adoption. From a portfolio construction view, this is a classic high-conviction, high-binary biotech exposure that should be sized for event-driven swings and hedged with time-limited protection.

Key Decisions for Investors

• CGEN — Tactical long (size 1–2% NAV): accumulate on weakness into the next 9–15 month translational readouts; hedge with a 9–12 month protective put ~25–30% OTM to cap downside. R/R: asymmetric — potential multiplex on a convincing monotherapy/maintenance signal vs limited, hedged loss if the small randomized cohort fails.
• AZN — Long-call-spread (24–30 month): buy a long-dated call / sell a higher-strike call (~+15–25%) to fund cost. Rationale: optionality on validation of a bispecific backbone across multiple combos with limited capital outlay; take profits into event-driven windows (data readouts) and roll into longer tenure if signals are favorable.
• Hedge/Pair — If you want to dampen binary biotech exposure, reduce net CGEN long via a small short position in pure-play TIGIT/TME small-caps (replaceable with focused ETFs or peers) or buy short-dated biotech put protection. Timeframe: protect over 6–12 months around translational and cohort updates.
• Risk trigger alerts: set automated alerts for (a) any broad tolerability signals from combo cohorts, (b) failure to replicate ex vivo-to-clinic correlation in early translational cohorts, and (c) formal regulatory feedback that narrows accelerated pathway prospects — any of which should prompt re-sizing within days.